- Home
- MOLN vs INMB Comparison
MOLN vs INMB Comparison
Compare MOLN & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- INMB
- Stock Information
- Founded
- MOLN 2004
- INMB 2015
- Country
- MOLN Switzerland
- INMB United States
- Employees
- MOLN N/A
- INMB N/A
- Industry
- MOLN
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- INMB Health Care
- Exchange
- MOLN Nasdaq
- INMB Nasdaq
- Market Cap
- MOLN 183.2M
- INMB 176.5M
- IPO Year
- MOLN 2021
- INMB 2019
- Fundamental
- Price
- MOLN $3.89
- INMB $6.38
- Analyst Decision
- MOLN
- INMB Strong Buy
- Analyst Count
- MOLN 0
- INMB 3
- Target Price
- MOLN N/A
- INMB $24.33
- AVG Volume (30 Days)
- MOLN 2.5K
- INMB 627.1K
- Earning Date
- MOLN 05-15-2025
- INMB 07-31-2025
- Dividend Yield
- MOLN N/A
- INMB N/A
- EPS Growth
- MOLN N/A
- INMB N/A
- EPS
- MOLN N/A
- INMB N/A
- Revenue
- MOLN $2,525,030.00
- INMB $50,000.00
- Revenue This Year
- MOLN N/A
- INMB $82.14
- Revenue Next Year
- MOLN $866.67
- INMB $28,750.98
- P/E Ratio
- MOLN N/A
- INMB N/A
- Revenue Growth
- MOLN N/A
- INMB N/A
- 52 Week Low
- MOLN $3.36
- INMB $4.32
- 52 Week High
- MOLN $12.70
- INMB $10.50
- Technical
- Relative Strength Index (RSI)
- MOLN 49.48
- INMB 37.45
- Support Level
- MOLN $3.76
- INMB $6.68
- Resistance Level
- MOLN $4.13
- INMB $8.05
- Average True Range (ATR)
- MOLN 0.18
- INMB 0.62
- MACD
- MOLN 0.01
- INMB -0.10
- Stochastic Oscillator
- MOLN 50.00
- INMB 10.31
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.